Is this e-mail displaying correctly? View this e-mail in your browser.
LOTEMAX /><sup>®</sup> Gel loteprednol etabonate 0.5%
Delivers a Consistent Dose in Every Drop1
Nonsettling properties of gel vs suspension—within 24 hours
�	LOTEMAX /><sup>®</sup> Gel loteprednol etabonate ophthalmic gel 0.5%
                    �	Drug particles did not settle with LOTEMAX<sup>®</sup> GEL over the full 24 hours of the study1
                    �	LOTEMAX<sup>®</sup> Gel loteprednol etabonate ophthalmic suspension 0.5%
                    �	LOTEMAX<sup>®</sup> SUSPENSION settled within 20 minutes1
Study tested the sedimentation behavior of LOTEMAX® GEL and LOTEMAX® SUSPENSION under 120g at 1000 rpm for 24 hours.1

Simulation demonstrated the nonsettling properties of the loteprednol particles in LOTEMAX® GEL and LOTEMAX® SUSPENSION under accelerated conditions.1
 
  •  In a study of patient compliance with ophthalmic corticosteroid suspensions, 63% of patients demonstrated a lack of compliance with shaking the bottle2
 
 
Indication
LOTEMAX® is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 
Important Risk Information
Contraindications:
•  LOTEMAX® is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
 
Warnings and Precautions:
•  Intraocular pressure (IOP) increase—Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
•  Cataracts—Use of corticosteroids may result in posterior subcapsular cataract formation.
•  Delayed healing—Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification.
•  Bacterial infections—Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infections.
•  Viral infections—Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex).
•  Fungal infections—Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
•  Contact lens wear—Patients should not wear contact lenses when using LOTEMAX®.
 
Adverse Reactions:
•  The most common ocular adverse drug reactions were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%).
 
Please see complete information about LOTEMAX® GEL in the full Prescribing Information provided here.
 
Please see complete information about LOTEMAX® SUSPENSION in the full Prescribing Information provided here.
 
For product-related questions and concerns, call 1-800-323-0000 or visit www.bausch.com.
 
LOTEMAX® Gel loteprednol etabonate 0.5%
Visit www.Lotemaxgel.com to order FREE LOTEMAX® GEL samples for your patients.
 
  References: 1. Coffey MJ, DeCory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299-312. 2. Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979;87(2):210-214.
 
BAUSCH + LOMB
LOTEMAX® is a registered trademark of
Bausch & Lomb Incorporated or its affiliates.

© 2014 Bausch & Lomb Incorporated. US/LGX/14/0027
LOTEMAX® Gel loteprednol etabonate ophthalmic suspension 0.5%
    If you no longer wish to receive e-mails from Bausch + Lomb about LOTEMAX® GEL, unsubscribe here.

 

Review of Ophthalmology® is published by the Review Group, a Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.

To subscribe to other JMI newsletters or to manage your subscription, click here.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add reviewophth@lists.jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Review of Ophthalmology.